Financial Review: Perspective Therapeutics (CATX) & Its Rivals

Perspective Therapeutics (NASDAQ:CATX) is one of 28 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its competitors? We will compare Perspective Therapeutics to similar companies based on the strength of its risk, dividends, earnings, valuation, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Perspective Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	N/A	N/A	N/A
Perspective Therapeutics Competitors	-672.41%	-133.75%	-59.01%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Perspective Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	0	6	0	3.00
Perspective Therapeutics Competitors	77	76	156	6	2.29

Perspective Therapeutics currently has a consensus price target of $11.17, indicating a potential upside of 137.59%. As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 45.75%. Given Perspective Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Perspective Therapeutics is more favorable than its competitors.

Insider & Institutional Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 3.7% of Perspective Therapeutics shares are owned by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Perspective Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, Perspective Therapeutics’ competitors have a beta of 1.76, meaning that their average share price is 76% more volatile than the S&P 500.

Earnings and Valuation

This table compares Perspective Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Perspective Therapeutics	N/A	N/A	-5.22
Perspective Therapeutics Competitors	$59.55 million	-$32.15 million	4.18

Perspective Therapeutics’ competitors have higher revenue, but lower earnings than Perspective Therapeutics. Perspective Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Perspective Therapeutics beats its competitors on 7 of the 12 factors compared.

About Perspective Therapeutics

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.